Drug
Belzutifan
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | HIF inhibitors |
| Group | HIF-2α inhibitor |
| Mechanism of Action | HIF-2α inhibitor |
| Half-life | 14 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing on theoretical grounds (↑p53, ROS/DNA damage, ↑apoptosis), unlike radioprotective HIF-1α inhibition (Semenza, Pharmacological Reviews, 2025; Bertout et al., PNAS, 2009). Any normal-tissue sensitization is theoretical and undefined; the recognized class effect of hypoxia/anemia could indirectly affect tumor oxygenation but is not an in-field adverse event per se.
Data on this page refer exclusively to patients treated with
Belzutifan combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
HIF-2α inhibitor group page.